New Re-invitation of applications under PLI Scheme for Bulk Drugs (Round-5).Last date of receipt of applications is 21st July 2025. Refer Scheme & Guidelines Section for detailed notice.
Applications invited for 11 identified bulk drug products (View detailed Notice).
Register & Apply
S. No. Production Process Name of Eligible Product Total Available Production Capacity (in MT)
1 Fermentation based products Erythromycin Thiocyanate 1,600
2Neomycin 160
3 Gentamycin 80
4 Clindamycin Base 120
5 Streptomycin 100
6 Tetracycline 400
7 Chemical Synthesis based products 2 MNI 3,200
8 Ciprofloxacin 600
9 Diclofenac Sodium 175
10 Dicyandiamide (DCDA) 24,000
11 1,1 Cyclohexane Diacetic Acid (CDA) 1,500

Register & Apply

Register

Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) In India.

Objective:

The objective of the Scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the Scheme, financial incentives shall be given based on threshold investment and domestic sales made by selected applicant for the eligible products.

Target Segments
Target Segment shall mean one of the four segments viz.:
i) Key Fermentation based KSMs / Drug Intermediates
ii) Niche Fermentation based KSMs / Drug Intermediates / APIs
iii) Key Chemical Synthesis based KSMs / Drug Intermediates
iv) Other Chemical Synthesis based KSMs / Drug Intermediates / APIs
Tenure of the Scheme

Financial Year 2020-21 to Financial Year 2029-30